Outcomes of High Initial Daily Doses of Gonadotropin in Patients With Poor Ovarian Reserve

Keay, 1997, Assisted conception following poor ovarian response to gonadotrophin stimulation, Br J Obstet Gynaecol, 104, 521, 10.1111/j.1471-0528.1997.tb11525.x

Out, 1999, A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation, Hum Reprod, 14, 622, 10.1093/humrep/14.3.622

Yong, 2003, A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment, Fertil Steril, 79, 308, 10.1016/S0015-0282(02)04583-1

Wikland, 2001, A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI, Hum Reprod, 16, 1676, 10.1093/humrep/16.8.1676

Out, 2004, A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction, Hum Reprod, 19, 90, 10.1093/humrep/deh044

Karande, 1990, High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients, Fertil Steril, 53, 486, 10.1016/S0015-0282(16)53345-7

Land, 1996, High-dose human menopausal gonadotropin stimulation in poor res-ponders does not improve in vitro fertilization outcome, Fertil Steril, 65, 961, 10.1016/S0015-0282(16)58269-7

van Hooff, 1993, Doubling the human menopausal gonado-trophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study, Hum Reprod, 8, 369, 10.1093/oxfordjournals.humrep.a138053

Klinkert, 2005, The antral follicle count is a better marker than basal follicle-stimulating hormone for the selection of older patients with acceptable pregnancy prospects after in vitro fertilization, Fertil Steril, 83, 811, 10.1016/j.fertnstert.2004.11.005

Feldberg, 1994, Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels, Fertil Steril, 62, 343, 10.1016/S0015-0282(16)56889-7

Dal Prato, 2001, Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: a randomized study, Hum Reprod, 16, 1409, 10.1093/humrep/16.7.1409

Nikolettos, 2001, Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders, Eur J Obstet Gynecol Reprod Biol, 97, 202, 10.1016/S0301-2115(00)00535-2

Craft, 1999, Will GnRH antagonists provide new hope for patients considered ‘difficult responders’ to GnRH agonist protocols?, Hum Reprod, 14, 2959, 10.1093/humrep/14.12.2959

Al-Inany, 2002, GnRH antagonist in assisted reproduction: a Cochrane review, Hum Reprod, 17, 874, 10.1093/humrep/17.4.874

Tomas, 1997, Pretreatment transvaginal ultrasound examination predicts ovarian responsiveness to gonadotrophins in in-vitro fertilization, Hum Reprod, 12, 220, 10.1093/humrep/12.2.220

Bancsi, 2004, Impact of repeated antral follicle counts on the prediction of poor ovarian response in women undergoing in vitro fertilization, Fertil Steril, 81, 35, 10.1016/j.fertnstert.2003.06.011

Hohmann, 2003, J Clin Endocrinol Metab, 88, 166, 10.1210/jc.2002-020788

Ragni, 2005, Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome, Hum Reprod, 20, 2421, 10.1093/humrep/dei074

Tarlatzis, 2003, Gonadotropin-releasing hormone antagonists: impact of IVF practice and potential nonassisted reproductive technology applications, Curr Opin Obstet Gynecol, 15, 259, 10.1097/00001703-200306000-00009

Al-Inany, 2001, Gonadotrophin-releasing hormone antagonists for assisted conception, Cochrane Database Syst Rev, 4, CD001750

Gordon, 2001, Gonadotropin-releasing hormone antagonists implications for oocyte quality and uterine receptivity, Ann N Y Acad Sci, 943, 49, 10.1111/j.1749-6632.2001.tb03789.x

Simon, 2005, Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared with treatment with a GnRH agonist or in natural cycles, Hum Reprod, 20, 3318, 10.1093/humrep/dei243